Repligen (NASDAQ:RGEN) Sees Large Volume Increase - Should You Buy?

Key Points

• Repligen shares experienced unusually high trading volume, with about 1.09 million shares changing hands, while the stock fell from a prior close of $188.64 to $173.36.
• Analyst sentiment remains positive: the stock has a consensus rating of “Moderate Buy” and an average price target of $178.57, with recent targets ranging from $160 to $200.
• Repligen exceeded quarterly expectations, reporting EPS of $0.53 versus a $0.46 estimate and revenue of $209.31 million, up 10.9% year over year; institutional investors own 97.64% of the company.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) shares saw unusually-strong trading volume on Friday. Approximately 1,089,652 shares were traded during trading, an increase of 3% from the average daily volume of 1,053,129 shares. The stock last traded at $173.3620 and had previously closed at $188.64.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RGEN shares. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. boosted their price target on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Royal Bank Of Canada raised their price objective on Repligen from $185.00 to $200.00 and gave the company an "outperform" rating in a research report on Wednesday. UBS Group reaffirmed a "buy" rating on shares of Repligen in a research note on Tuesday, September 29th. Finally, Evercore reiterated an "outperform" rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.57.

Repligen Stock Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.64 and a current ratio of 9.88. The stock's 50-day simple moving average is $178.12 and its 200 day simple moving average is $145.19. The company has a market cap of $9.84 billion, a PE ratio of -832.18, a P/E/G ratio of 3.35 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm had revenue of $209.31 million during the quarter, compared to analysts' expectations of $206.70 million. During the same quarter in the prior year, the business posted $0.46 earnings per share. Repligen's revenue was up 10.9% compared to the same quarter last year. As a group, equities analysts anticipate that Repligen Corporation will post 2.07 EPS for the current year.

Institutional Trading of Repligen

A number of large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in Repligen in the 2nd quarter worth $52,000. CoreCap Advisors LLC boosted its stake in shares of Repligen by 1,275.0% during the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 255 shares in the last quarter. Harbor Investment Advisory LLC boosted its holdings in Repligen by 198.9% in the second quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 348 shares during the last quarter. Trust Co. of Vermont acquired a new position in shares of Repligen during the second quarter worth approximately $71,000. Finally, Allworth Financial LP bought a new position in shares of Repligen during the 2nd quarter worth approximately $71,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.